Aspen Aerogels: Green Shoots Fail To Truly Impress Investors

Aspen Aerogels delivered sequential revenue and EBITDA improvement, with Q2 revenues topping guidance and Q3 outlook signaling further recovery. Thermal Barrier sales rebounded sequentially, especially in Europe, but remain pressured by regulatory shifts and evolving battery technologies. ASPN's EBITDA break-even threshold lowered to $175 million in annual revenue, reflecting cost discipline and operational progress despite fire-related disruptions. Despite positive momentum, conviction is tempered by execution history, capital allocation concerns, and competitive risks from alternative battery technologies.

Shares of Aspen Aerogels ( ASPN ) hit the news wires again last week, showing tremendous volatility as investors digest the news flow on the outlook for the business. Shares jumped from $5 to $8 per share